Monopar Therapeutics MNPR Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's tax on share settlement?
- Monopar Therapeutics (MNPR) reported tax on share settlement of $200.2K in Q1 2026.
- How has Monopar Therapeutics's tax on share settlement changed year-over-year?
- Monopar Therapeutics's tax on share settlement increased by 52.7% year-over-year, from $131.13K to $200.2K.
- What is the long-term trend for Monopar Therapeutics's tax on share settlement?
- Over 2 years (2023 to 2025), Monopar Therapeutics's tax on share settlement has grown at a 391.0% compound annual growth rate (CAGR), from $46.97K to $1.13M.
- What does tax on share settlement mean?
- Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.